Silk Road Medical Inc SILK
We take great care to ensure that the data presented and summarized in this overview for Silk Road Medical Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SILK
View all-
Wasatch Advisors Inc Salt Lake City, UT4.55MShares$99.8 Million0.44% of portfolio
-
Capital World Investors Los Angeles, CA3.11MShares$68.2 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.97MShares$65.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$64.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.83MShares$40.2 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.6MShares$35.1 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.52MShares$33.3 Million0.44% of portfolio
-
Bamco Inc New York, NY1.5MShares$32.9 Million0.07% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA1.19MShares$26.1 Million1.27% of portfolio
-
Tri Locum Partners LP New York, NY1.08MShares$23.8 Million7.14% of portfolio
Latest Institutional Activity in SILK
Top Purchases
Top Sells
About SILK
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Insider Transactions at SILK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2024
|
Kevin J. Ballinger |
BUY
Open market or private purchase
|
Direct |
11,700
+39.65%
|
$187,200
$16.99 P/Share
|
|
Mar 05
2024
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
SELL
Open market or private sale
|
Direct |
3,800
-1.81%
|
$64,600
$17.17 P/Share
|
|
Mar 05
2024
|
Lucas W. Buchanan COO/CFO |
SELL
Open market or private sale
|
Direct |
9,877
-1.93%
|
$167,909
$17.17 P/Share
|
|
Mar 05
2024
|
Andrew S. Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,481
-1.87%
|
$93,177
$17.17 P/Share
|
|
Mar 05
2024
|
Marie L. Jones VP, Finance and CAO |
SELL
Open market or private sale
|
Direct |
2,602
-3.27%
|
$44,234
$17.17 P/Share
|
|
Mar 05
2024
|
Kevin M Klemz EVP/Chief Legal Officer/Sec. |
SELL
Open market or private sale
|
Direct |
2,497
-1.49%
|
$42,449
$17.17 P/Share
|
|
Mar 01
2024
|
Lucas W. Buchanan COO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
74,954
+12.8%
|
-
|
|
Mar 01
2024
|
Andrew S. Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,201
+17.5%
|
-
|
|
Mar 01
2024
|
Marie L. Jones VP, Finance and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
24,555
+23.6%
|
-
|
|
Mar 01
2024
|
Kevin M Klemz EVP/Chief Legal Officer/Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
42,818
+20.34%
|
-
|
|
Mar 01
2024
|
Chas Mc Khann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,313
+13.25%
|
-
|
|
Mar 01
2024
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
BUY
Grant, award, or other acquisition
|
Direct |
38,674
+15.58%
|
-
|
|
Feb 29
2024
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
SELL
Open market or private sale
|
Direct |
3,000
-1.73%
|
$66,000
$22.25 P/Share
|
|
Nov 02
2023
|
Chas Mc Khann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
612,083
+50.0%
|
-
|
|
Oct 27
2023
|
Marie L. Jones VP, Finance and CAO |
SELL
Open market or private sale
|
Direct |
656
-1.18%
|
$3,936
$6.61 P/Share
|
|
Oct 04
2023
|
Lucas W. Buchanan COO/CFO |
SELL
Open market or private sale
|
Direct |
2,662
-0.61%
|
$39,930
$15.22 P/Share
|
|
Sep 15
2023
|
Richard Ruedy EVPClin&Reg.Affairs&QA |
BUY
Grant, award, or other acquisition
|
Direct |
28,354
+14.02%
|
-
|
|
Sep 15
2023
|
Kevin M Klemz EVP/Chief Legal Officer/Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
86,076
+40.8%
|
-
|
|
Sep 15
2023
|
Marie L. Jones VP, Finance and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
7,595
+12.02%
|
-
|
|
Sep 15
2023
|
Lucas W. Buchanan COO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
222,785
+22.62%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.46M shares |
|---|---|
| Exercise of conversion of derivative security | 13.6K shares |
| Open market or private purchase | 11.7K shares |
| Open market or private sale | 40.8K shares |
|---|